High plasma thiocyanate levels are associated with enhanced myeloperoxidase-induced thiol oxidation and long-term survival in subjects following a first myocardial infarction

References

• Davies MJ, Hawkins CL, Pattison DI, Rees MD. Mammalian heme peroxidases: from molecular mechanisms to health implications. Antioxid Redox Signal 2008;10:1199–1234.
   PubMed Web of Science ®Google Scholar
• van der Veen BS, de Winther MP, Heeringa P. Myeloperoxidase: molecular mechanisms of action and their relevance to human health and disease. Antioxid Redox Signal 2009;11:2899–2937.
   PubMed Web of Science ®Google Scholar
• Nicholls SJ, Hazen SL. Myeloperoxidase and cardiovascular disease. Arterioscler Thromb Vasc Biol 2005;25: 1102–11011.
   PubMed Web of Science ®Google Scholar
• Rudolph TK, Rudolph V, Baldus S. Contribution of myeloperoxidase to smoking-dependent vascular inflammation. Proc Am Thorac Soc 2008;5:820–823.
   PubMedGoogle Scholar
• Morgan PE, Pattison DI, Talib J, Summers FA, Harmer JA, Celermajer DS, et al. High plasma thiocyanate levels in smokers are a key determinant of thiol oxidation induced by myeloperoxidase. Free Radic Biol Med 2011;51:1815–1822.
   PubMed Web of Science ®Google Scholar
• van Dalen CJ, Whitehouse MW, Winterbourn CC, Kettle AJ. Thiocyanate and chloride as competing substrates for myeloperoxidase. Biochem J 1997;327:487–492.
   PubMed Web of Science ®Google Scholar
• Hurst JK. What really happens in the neutrophil phagosome? Free Radic Biol Med 2012;53:508–520.
   PubMedGoogle Scholar
• Daugherty A, Dunn JL, Rateri DL, Heinecke JW. Myeloperoxidase, a catalyst for lipoprotein oxidation, is expressed in human atherosclerotic lesions. J Clin Invest 1994;94: 437–444.
   PubMed Web of Science ®Google Scholar
• Hazell LJ, Arnold L, Flowers D, Waeg G, Malle E, Stocker R. Presence of hypochlorite-modified proteins in human atherosclerotic lesions. J Clin Invest 1996;97:1535–1544.
   PubMed Web of Science ®Google Scholar
• Henderson JP, Byun J, Takeshita J, Heinecke JW. Phagocytes produce 5-chlorouracil and 5-bromouracil, two mutagenic products of myeloperoxidase, in human inflammatory tissue. J Biol Chem 2003;278:23522–23528.
   PubMed Web of Science ®Google Scholar
• Takeshita J, Byun J, Nhan TQ, Pritchard DK, Pennathur S, Schwartz SM, et al. Myeloperoxidase generates 5-chlorouracil in human atherosclerotics tissue: A potential pathway for somatic mutagenesis by macrophages. J Biol Chem 2005;281:3096–3104.
   PubMed Web of Science ®Google Scholar
• Hazen SL, Gaut JP, Crowley JR, Hsu FF, Heinecke JW. Elevated levels of protein-bound p-hydroxyphenylacetaldehyde, an amino- acid-derived aldehyde generated by myeloperoxidase, are present in human fatty streaks, intermediate lesions and advanced atherosclerotic lesions. Biochem J 2000;352:693–699.
   PubMed Web of Science ®Google Scholar
• Thukkani AK, McHowat J, Hsu FF, Brennan ML, Hazen SL, Ford DA. Identification of alpha-chloro fatty aldehydes and unsaturated lysophosphatidylcholine molecular species in human atherosclerotic lesions. Circulation 2003;108: 3128–3133.
   PubMed Web of Science ®Google Scholar
• Hawkins CL. The role of hypothiocyanous acid (HOSCN) in biological systems. Free Radic Res 2009;43:1147–1158.
   PubMed Web of Science ®Google Scholar
• Pattison DI, Davies MJ, Hawkins CL. Reactions and reactivity of myeloperoxidase-derived oxidants: differential biological effects of hypochlorous and hypothiocyanous acids. Free Radic Res 2012;46:975–995.
   PubMed Web of Science ®Google Scholar
• Wang Z, Nicholls SJ, Rodriguez ER, Kummu O, Horkko S, Barnard J, et al. Protein carbamylation links inflammation, smoking, uremia and atherogenesis. Nat Med 2007;13: 1176–1184.
   PubMed Web of Science ®Google Scholar
• Botti TP, Amin H, Hiltscher L, Wissler RW. A comparison of the quantitation of macrophage foam cell populations and the extent of apolipoprotein E deposition in developing atherosclerotic lesions in young people: high and low serum thiocyanate groups as an indication of smoking. Atherosclerosis 1996;124:191–202.
   PubMed Web of Science ®Google Scholar
• Scanlon CEO, Berger B, Malcom G, Wissler RW. Evidence for more extensive deposits of epitopes of oxidized low density lipoproteins in aortas of young people with elevated serum thiocyanate levels. Atherosclerosis 1996;121:23–33.
   PubMed Web of Science ®Google Scholar
• Holzer M, Gauster M, Pfeifer T, Wadsack C, Fauler G, Stiegler P, et al. Protein carbamylation renders high-density lipoprotein dysfunctional. Antioxid Redox Signal 2011; 14:2337–2346.
   PubMed Web of Science ®Google Scholar
• Xu Y, Szep S, Lu Z. The antioxidant role of thiocyanate in the pathogenesis of cystic fibrosis and other inflammation-related diseases. Proc Natl Acad Sci U S A 2009;106:20515–20519.
   PubMed Web of Science ®Google Scholar
• Bozonet SM, Scott-Thomas AP, Nagy P, Vissers MC. Hypothiocyanous acid is a potent inhibitor of apoptosis and caspase 3 activation in endothelial cells. Free Radic Biol Med 2010;49:1054–1063.
   PubMed Web of Science ®Google Scholar
• Malisoff WM, Marine D. Prevention of atherosclerosis in rabbits. 1. Administration of potassium thiocyanate. Proc Soc Exp Biol Med 1936;35:356–358.
   Google Scholar
• Barrett TJ, Hawkins CL. Hypothiocyanous acid: benign or deadly? Chem Res Toxicol 2012;25:263–273.
   PubMed Web of Science ®Google Scholar
• Chandler JD, Day BJ. Thiocyanate: a potentially useful therapeutic agent with host defense and antioxidant properties. Biochem Pharmacol 2012;84:1381–1387.
   PubMed Web of Science ®Google Scholar
• O’Donnell CJ, Kannel WB. Epidemiology of atherosclerotic vascular disease. In: Lanzer PT, Topel EJ (eds.). Panvascular Medicine. Berlin: Springer-Verlag; 2003.
   Google Scholar
• World Health Organisation, Report of the global tobacco epidemic, 2011. Geneva.
   Google Scholar
• Wilson J. Cyanide in human disease: a review of clinical and laboratory evidence. Fundam Appl Toxicol 1983;3:397–399.
   PubMedGoogle Scholar
• Cipollone R, Ascenzi P, Tomao P, Imperi F, Visca P. Enzymatic detoxification of cyanide: clues from Pseudomonas aeruginosa Rhodanese. J Mol Microbiol Biotechnol 2008;15:199–211.
   PubMed Web of Science ®Google Scholar
• Spagnolo A, Torsello S, Morisi G, Petrozzi E, Antonini R, Ricci G, et al. Serum thiocyanate levels as an objective measure of smoking habits in epidemiological studies. Eur J Epidemiol 1988;4:206–211.
   PubMed Web of Science ®Google Scholar
• Vetter J. Plant cyanogenic glycosides. Toxicon 2000;38:11–36.
   PubMed Web of Science ®Google Scholar
• Vesey CJ, Cole PV. Blood cyanide and thiocyanate concentrations produced by long-term therapy with sodium nitroprusside. Br J Anaesth 1985;57:148–155.
   PubMed Web of Science ®Google Scholar
• U.S. Environmental Protection Agency. Toxicological review of acetonitrile Washington, DC 1999.
   Google Scholar
• Talib J, Pattison DI, Harmer JA, Celermajer DS, Davies MJ. High plasma thiocyanate levels modulate protein damage induced by myeloperoxidase and perturb measurement of 3-chlorotyrosine. Free Radic Biol Med 2012;53:20–29.
   PubMed Web of Science ®Google Scholar
• Pattison DI, Davies MJ. Reactions of myeloperoxidase-derived oxidants with biological substrates: gaining insight into human inflammatory diseases. Curr Med Chem 2006;13: 3271–3290.
   PubMed Web of Science ®Google Scholar
• Skaff O, Pattison DI, Davies MJ. Hypothiocyanous acid reactivity with low-molecular-mass and protein thiols: Absolute rate constants and assessment of biological relevance. Biochem J 2009;422:111–117.
   PubMed Web of Science ®Google Scholar
• Nagy P, Jameson GN, Winterbourn CC. Kinetics and mechanisms of the reaction of hypothiocyanous acid with 5-thio-2-nitrobenzoic acid and reduced glutathione. Chem Res Toxicol 2009;22:1833–1840.
   PubMed Web of Science ®Google Scholar
• Skaff O, Pattison DI, Morgan PE, Bachana R, Jain VK, Priyadarsini KI, Davies MJ. Selenium-containing amino acids are major targets for myeloperoxidase-derived hypothiocyanous acid: determination of absolute rate constants and implications for biological damage. Biochem J 2012;441:305–316.
   PubMed Web of Science ®Google Scholar
• Ashfaq S, Abramson JL, Jones DP, Rhodes SD, Weintraub WS, Hooper WC, et al. The relationship between plasma levels of oxidized and reduced thiols and early atherosclerosis in healthy adults. J Am Coll Cardiol 2006;47:1005–1111.
   PubMed Web of Science ®Google Scholar
• Huang YS, Wang LX, Sun L, Wu Y, Lu JM, Zhao SC, et al. Elevated peroxidative glutathione redox status in atherosclerotic patients with increased thickness of carotid intima media. Chin Med J 2009;122:2827–2832.
   PubMedGoogle Scholar
• Schutte R, Schutte AE, Huisman HW, van Rooyen JM, Malan NT, Peter S, et al. Blood glutathione and subclinical atherosclerosis in African men: the SABPA Study. Am J Hypertension 2009;22:1154–1159.
   PubMed Web of Science ®Google Scholar
• Gould NS, Gauthier S, Kariya CT, Min E, Huang J, Brian DJ. Hypertonic saline increases lung epithelial lining fluid glutathione and thiocyanate: two protective CFTR-dependent thiols against oxidative injury. Resp Res 2010;11:119.
   PubMed Web of Science ®Google Scholar
• Ashby MT, Carlson AC, Scott MJ. Redox buffering of hypochlorous acid by thiocyanate in physiologic fluids. J Am Chem Soc 2004;126:15976–15977.
   PubMed Web of Science ®Google Scholar
• Xulu BA, Ashby MT. Small molecular, macromolecular, and cellular chloramines react with thiocyanate to give the human defense factor hypothiocyanite. Biochemistry 2010;49: 2068–2074.
   PubMed Web of Science ®Google Scholar
• Nagy P, Beal JL, Ashby MT. Thiocyanate is an efficient endogenous scavenger of the phagocytic killing agent hypobromous acid. Chem Res Toxicol 2006;19:587–593.
   PubMed Web of Science ®Google Scholar
• Lloyd MM, van Reyk DM, Davies MJ, Hawkins CL. Hypothiocyanous acid is a more potent inducer of apoptosis and protein thiol depletion in murine macrophage cells than hypochlorous acid or hypobromous acid. Biochem J 2008;414:271–280.
   PubMed Web of Science ®Google Scholar
• Nelson DP, Kiesow LA. Enthalpy of decomposition of hydrogen peroxide by catalase at 25°C (with molar extinction coefficients of H2O2 solutions in the UV). Anal Biochem 1972;49:474–478.
   PubMed Web of Science ®Google Scholar
• Borawski J. Myeloperoxidase as a marker of hemodialysis biocompatibility and oxidative stress: the underestimated modifying effects of heparin. Am J Kidney Dis 2006;47: 37–41.
   PubMed Web of Science ®Google Scholar
• Baldus S, Rudolph V, Roiss M, Ito WD, Rudolph TK, Eiserich JP, et al. Heparins increase endothelial nitric oxide bioavailability by liberating vessel-immobilized myeloperoxidase. Circulation 2006;113:1871–1878.
   PubMed Web of Science ®Google Scholar
• Mocatta TJ, Pilbrow AP, Cameron VA, Senthilmohan R, Frampton CM, Richards AM, Winterbourn CC. Plasma concentrations of myeloperoxidase predict mortality after myocardial infarction. J Am Coll Cardiol 2007;49:1993–2000.
   PubMed Web of Science ®Google Scholar
• Agnelli G, Sonaglia F. Perspectives on antithrombotic agents: from unfractionated heparin to new antithrombotics. Haematologica 2002;87:757–770.
   PubMedGoogle Scholar
• Hawkins CL, Morgan PE, Davies MJ. Quantification of protein modification by oxidants. Free Radic Biol Med 2009;46:965–988.
   PubMed Web of Science ®Google Scholar
• Winterbourn CC. Reconciling the chemistry and biology of reactive oxygen species. Nat Chem Biol 2008;4:278–286.
   PubMed Web of Science ®Google Scholar
• Winterbourn CC, Hampton MB, Livesey JH, Kettle AJ. Modeling the reactions of superoxide and myeloperoxidase in the neutrophil phagosome: implications for microbial killing. J Biol Chem 2006;281:39860–39869.
   PubMed Web of Science ®Google Scholar
• Fonarow GC, Abraham WT, Albert NM, Stough WG, Gheorghiade M, Greenberg BH, et al. A smoker's paradox in patients hospitalized for heart failure: findings from OPTIMIZE-HF. Eur Heart J 2008;29:1983–1991.
   PubMedGoogle Scholar
• Katayama T, Iwasaki Y, Sakoda N, Yoshioka M. The etiology of'smoker's paradox’ in acute myocardial infarction with special emphasis on the association with inflammation. Int Heart J 2008;49:13–24.
   PubMedGoogle Scholar
• Heliovaara M, Karvonen MJ, Punsar S, Rautanen Y, Haapakoski J. Serum thiocyanate concentration and cigarette smoking in relation to overall mortality and to deaths from coronary heart disease and lung cancer. J Chronic Dis 1981;34:305–311.
   PubMedGoogle Scholar
• Maliszewski TF, Bass DE. True and apparent thiocyanate in body fluids of smokers and nonsmokers. J Appl Physiol 1955;8:289–291.
   PubMed Web of Science ®Google Scholar
• Strong JP. Natural history and risk factors for early human atherogenesis. Pathobiological Determinants of Atherosclerosis in Youth (PDAY) Research Group. Clin Chem 1995;41: 134–138.
   Google Scholar
• Ockene JK, Kuller LH, Svendsen KH, Meilahn E. The relationship of smoking cessation to coronary heart disease and lung cancer in the Multiple Risk Factor Intervention Trial (MRFIT). Am J Public Health 1990;80:954–958.
   PubMed Web of Science ®Google Scholar
• Brennan ML, Penn MS, Van Lente F, Nambi V, Shishehbor MH, Aviles RJ, et al. Prognostic value of myeloperoxidase in patients with chest pain. N Engl J Med 2003;349: 1595–1604.
   PubMed Web of Science ®Google Scholar
• Rudolph V, Goldmann BU, Bos C, Rudolph TK, Klinke A, Friedrichs K, et al. Diagnostic value of MPO plasma levels in patients admitted for suspected myocardial infarction. Int J Cardiol 2010;153:267–271.
   PubMedGoogle Scholar
• Nicholls SJ, Wilson Tang WH, Brennan D, Brennan ML, Mann S, Nissen SE, Hazen SL. Risk prediction with serial myeloperoxidase monitoring in patients with acute chest pain. Clin Chem 2011;57:1762–1770.
   PubMed Web of Science ®Google Scholar
• Tang WH, Wu Y, Nicholls SJ, Hazen SL. Plasma myeloperoxidase predicts incident cardiovascular risks in stable patients undergoing medical management for coronary artery disease. Clin Chem 2011;57:33–39.
   PubMed Web of Science ®Google Scholar
• Tang WHW, Brennan ML, Philip K, Tong W, Mann S, Van Lente F, Hazen SL. Plasma myeloperoxidase levels in patients with chronic heart failure. Am J Cardiol 2006;98: 796–799.
   PubMed Web of Science ®Google Scholar
• Heslop CL, Frohlich JJ, Hill JS. Myeloperoxidase and C-reactive protein have combined utility for long-term prediction of cardiovascular mortality after coronary angiography. J Am Coll Cardiol 2010;55:1102–1109.
   PubMed Web of Science ®Google Scholar
• Pattison DI, Hawkins CL, Davies MJ. What are the plasma targets of the oxidant hypochlorous acid? A kinetic modeling approach. Chem Res Toxicol 2009;22:807–817.
   PubMed Web of Science ®Google Scholar
• Requejo R, Hurd TR, Costa NJ, Murphy MP. Cysteine residues exposed on protein surfaces are the dominant intramitochondrial thiol and may protect against oxidative damage. FEBS J 2010;277:1465–1480.
   PubMed Web of Science ®Google Scholar
• Barrett TJ, Pattison DI, Leonard SE, Carroll KS, Davies MJ, Hawkins CL. Inactivation of thiol-dependent enzymes by hypothiocyanous acid: role of sulfenyl thiocyanate and sulfenic acid intermediates. Free Radic Biol Med 2012;52: 1075–1085.
   PubMed Web of Science ®Google Scholar
• Lentner C (ed.). Geigy scientific tables: physical chemistry, composition of blood, hematology, somatometric data, volume 3. Basle: Ciba-Geigy Ltd; 1984.
   Google Scholar
• Aune E, Roislien J, Mathisen M, Thelle DS, Otterstad JE. The “smoker's paradox” in patients with acute coronary syndrome: a systematic review. BMC Med 2011;9:97.
   PubMedGoogle Scholar
• Aune TM, Thomas EL. Oxidation of protein sulfhydryls by products of peroxidase-catalyzed oxidation of thiocyanate ion. Biochemistry 1978;17:1005–1010.
   PubMed Web of Science ®Google Scholar
• Foss OP, Lund-Larsen PG. Serum thiocyanate and smoking: interpretation of serum thiocyanate levels observed in a large health study. Scand J Clin Lab Invest 1986;46:245–251.
   PubMed Web of Science ®Google Scholar